Targeted therapies and immunotherapies have revolutionized cancer treatment in recent years. However, achieving durable responses and, ultimately, curing metastatic cancers driven by intracellular oncogenes remains a primary unmet medical need. Although fragments of intracellular oncoproteins can act as neoantigens presented by the major histocompatibility complex (MHC), recognizing the typically minimal differences between oncoproteins and their normal counterparts makes this approach quite challenging.